Menu
CALL US : 02 651 5988

Medical Service

Erectile dysfunction is treatable. Treatments for erectile dysfunction.

โทรศัพท์ : 026515988
Powered by Shopable
Erectile dysfunction is treatable. Treatments for erectile dysfunction.
Erectile dysfunction is treatable. Treatments for erectile dysfunction.

Cardio
Cancer
Diabetes
Allergies
SLE
Menopause
Chronic Fatigue
Bones and
Degenerative
Chronic pain
Spondylosis
Alzheimer
Personalized Vitamin
Gastrointestinal Diseases
Parkinsons
Surviving Stroke
Thyroid Disease
rheumatoid
Kidney Disease
Erectile dysfunction
Liver Disease

Basic Care

A change in lifestyle is a significant component in the majority of circumstances. Treating physicians often advocate regular exercise, a focus on foods like vegetables and fruits, or Mediterranean-style diets, as well as eliminating smoking and drinking alcohol. All of the aforementioned changes would have a positive effect on a person's blood glucose, cholesterol, and blood pressure levels, helping to improve body function, including erectile dysfunction. Aside from that, managing physicians will typically ask about the patient's current medications, since some of them may have an adverse effect that is the core cause of the patient's erection problem.

General treatment of erectile dysfunction

Commonly, the most treatments are based on the patient's symptoms. However, in most cases, these treatments are not permanent because they do not address the underlying cause of the problem.

  • Method 1: One of the quick fixes is the usage of Phosphodiesterase-5 (PDE5) inhibitor class drugs. It works by increasing circulation by enlarging the arteries in the genitals. The better the blood flow through the penis, the better the erection. The primary component found in this class of drugs is cGMP, or cyclic guanosine monophosphate.

    The mechanism of action is driven by the nitric oxide properties. However, it is naturally controlled when it is forms. The enzyme Phosphodiesterase-5 naturally breaks down cGMP (PDE5) and helps to prolong the duration of the erection. Some of the brands under this category are as follows; Sildenafil or Viagra, Vardenafil or Levitra, and Tadalafil or Cialis®.

  • Method 2: The employment of a vacuum cylinder penis pump is method number two.This way of treating erectile dysfunction is usually reserved for those who have found the first method to be ineffective or who have secondary medical conditions that preclude them from taking the class of medications listed in Method 1. This approach has been shown to be completely safe. However, there is a drawback to the situation. Erections are usually short-lived, and they can also alter the user's ejaculation. According to studies, the rate of performance is around 70% –80%, and the percentage of satisfaction is low in real-world application.

  • Method 3: The third method involves inserting the medication through the urethra known as Prostaglandin E1. This medication is approximately the size of a grain of rice. The patient must first urinate before inserting the tiny pills into the urethra. After being inserted, the medication dissolves and is absorbed into the penis muscles. The effectiveness of this type of medication ranges between 50 and 65 percent. Relative to the cost, side effects include urethral burning and erratic performance. As a result, for many people, Prostaglandin E1 is not the treatment of choice.
  • Method 4: Medical injection directly into the penis is one of the most commonly used methods. However, these PDE-5 inhibitor injections are not that effective. The blood vessels expand and then harden. Some examples of such injections are: papaverine, prostaglandin E1 or Alprostadil, phentolamine, and atropine.

    There are several side-effects to these methods, such as the pain of the actual injection, erections lasting longer than expected (priapism), bleeding or bruising at the injection site, as well as scarring.

    Patients should not increase the dose of the injection by themselves without consulting a doctor. The managing physician should also be informed of the patient’s medication regime in order to prevent any adverse effects.

  • Method 5: Using Shock Wave or Sound Wave Therapy is reportedly effective in treating patients with erectile dysfunction who do not respond to medications such as PDE5 inhibitors. This treatment is believed to improve the circulatory system in the genitals. It causes the cells lining of the blood vessels to grow and then stimulates stem cells in the genitals.

    In 2012, research studies showed that the use of shock wave to treat sexual dysfunction showed positive results among people who had previously responded to PDE5 inhibitors and had no side effects. Another study was conducted on 29 patients who were resistant to PDE5 inhibitors and found that shock wave therapy works well.

  • Method 6 is genital augmentation. This method is used when other methods do not work. This method involves inserting the device into the genital area. This device helps with patients’ erection. However, the side effects of using such a device are abrasion, leakage, infection, and device malfunction.

Alternative treatment of erectile dysfunction

Chemicals are used in some of the aforementioned treatments, particularly when oral medications are used. These medications can sometimes have a lot of adverse effects or contraindications. As a result, using natural-based nutrients may be a preferable choice. The following are some examples:

  1. Yohimbine is a naturally derived compound produced from the Yohimbine tree's bark. It is a natural substance that was widely utilized prior to the development of the PDE-5 inhibitor group. Yohimbine has also been demonstrated to be effective in the treatment of erectile dysfunction.
  2. Arginine is an amino acid or subunit protein that aids in the conversion of Nitric Oxide, which causes blood vessels to dilate. In a European trial of 124 men aged 30 to 50 with moderate erectile dysfunction, arginine was found to be more effective than medications in the PDE5 group.
  3. Ginseng is another type of natural medicine that is frequently used to treat erectile dysfunction. A study on 349 patients was conducted and found to be effective. However, due to the collection process, the data collection methodology is not official, and thus the results are not conclusive.

Stem Cell Therapy

To date, most treatments for erectile dysfunction are symptomatic, and does not cure or rehabilitated the actual problem.  Drug resistance problems were also found in the PDE-5 inhibitors group in about 20% for people without medical conditions. However, if you have diabetes or have had prostate surgery before, the chance of drug resistance increases to 40 %.

 

Therefore, efforts have been made to find other ways to help, such as injecting chemical-based medicaments into the genital area, the use of vacuum cylinders or even genital augmentation surgery. However, there are limitations to these treatments due to factors such as high cost, side-effects, tolerance of pain during treatments or skimpily poor results. Therefore, there is a need to try to find effective and curable treatments for people with erectile dysfunction, leading the medical community to focus on stem cell use.

 

Stem cells are cells capable of regenerating themselves or developing into special cells. Studies have shown that stem cell can stimulate the tissue to trigger repaired or self-regenerated.  This makes it possible to treat damaged tissues. There has been a lot of research on the use of stem cells to treat erectile dysfunction, which appears to have satisfactory results. In this research stem cells injected are injected into the genital area with proven excellent results.

Published in 2010 by a research team from Korea, the research was based on umbilical cord tissue stem cells of 10 million cells. A study was conducted on seven men aged 57- to 83 who had erectile dysfunction problems due to diabetes. The study showed that, most of them had mooring erection within a month of the injection.  The effects lasted more than 6 months and was also lower blood glucose levels 2 weeks after the injection. This indicates that stem cell therapy from the umbilical cord, helps those with both erectile dysfunction and diabetes.

 

Another important study in 2016, was phase 1 research comparing stem cell use from bone marrow in patients with erectile dysfunction who had previously undergone prostate surgery. By giving in cell counts, dividing patients into four groups and providing stem cells of; 20 million cells, 200 million cells, 1 billion cells, and 2 billion cells.  The treatments all worked well without any side-effects. For those who receive the highest amount, were given 6 months follow ups and subsequent phase 2 studies concluded that 1 billion cells have the best efficacy for the erectile dysfunction treatment.

 

Research on stem cell use for erectile dysfunction has been on going. Apart from the above mentioned, five more studies with a total of 61 patients in phases 1 and 2 with follow-ups ranging from 6 months to 62 months. These studies concluded that stem cell use had a positive effect in treating erectile dysfunction and had no side effects. Therefore, it is a treatment that has the highest potential to help those with erectile dysfunction problems.

 

References:

  1. Kolodny L. (2011) Chapter 17: Men’s Health: Erectile Dysfunction (pg. 971). In: Bope E., Kellerman R. (Eds.), Conn's Current Therapy (1st ed). Saunders, An Imprint of Elsevier.
  2. Heidelbaugh JJ. Management of erectile dysfunction. Am Fam Physician. 2010;81(3):305-312.
  3. Wolfe SM. There have been inadequate warnings that erectile dysfunction drugs can cause blindness: MedGenMed. 2005 Dec 5;7(4):61.
  4. Pomeranz HD. Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy. Neurol Clin. 2017 Feb;35(1):17-27.
  5. Thakur JS, Thakur S, Sharma DR, Mohindroo NK, Thakur A, Negi PC. Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil. Laryngoscope. 2013 Jun;123(6):1527-30.
  6. Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011 May;121(5):1049-54.
  7. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope. 2009 Aug;119(8):1586-9.
  8. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clin Proc. 2012;87(8):766-778.
  9. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol. 2004 Jun;171(6 Pt 1):2358-62, quiz 2435.
  10. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS., Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016 Feb 18;374(7):611-24.
  11. Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, McGettigan J, Dowsett SA, Hayes RP, Knorr J, Ni X, Kinchen K. Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. J Urol. 2016 Mar;195(3):699-705.
  12. Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017 Dec;72(6):1000-1011.
  13. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9.
  14. 14.Pinsky MR, Chawla A, Hellstrom WJ.Intracavernosal therapy and vacuum devices to treat erectile dysfunction.Archivosespanoles de urologia. Oct 2010; 63(8):717-725
  15. Rew KT, Heidelbaugh JJ. Erectile Dysfunction. Am Fam Physician. 2016 Nov 15;94(10):820-827.
  16. Khayyamfar F, Forootan SK, Ghasemi H, Miri SR, Farhadi E. Evaluating the efficacy of vacuum constrictive device and causes of its failure in impotent patients. Urol J. 2014 Jan 04;10(4):1072-8.
  17. Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama à Nijeholt GA, Lynch SF, Morgan RJ, Müller SC, Porst H, Pryor JP, Ryan P, Witzsch UK, Hall MM, Place VA, Spivack AP, Gesundheit N. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998 Jun;81(6):889-94.
  18. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997 Jan 02;336(1):1-7.
  19. Rew KT, Heidelbaugh JJ. Erectile Dysfunction. Am Fam Physician. 2016 Nov 15;94(10):820-827.
  20. Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019 Jun;37(6):1007-1014.
  21. Hedlund H, Hedlund P. Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models. Scand J Urol Nephrol Suppl. 1996;179:129-38.
  22. Armstrong DK, Convery A, Dinsmore WW. Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J STD AIDS. 1993 Jul-Aug;4(4):214-6.
  23. Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple-drug therapy in a pharmacological erection program. J Urol. 1993 Dec;150(6):1822-4.
  24. Shenfeld O, Hanani J, Shalhav A, Vardi Y, Goldwasser B. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol. 1995 Sep;154(3):1017-9.
  25. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996 Apr 04;334(14):873-7.
  26. Angulo JC, Arance I, de Las Heras MM, Meilán E, Esquinas C, Andrés EM. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. Actas Urol Esp. 2017 Oct;41(8):479-490.
  27. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol. 2017 Feb;71(2):223-233.
  28. Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017 Jan;14(1):27-35.
  29. Dong L, Chang D, Zhang X, Li J, Yang F, Tan K, Yang Y, Yong S, Yu X. Effect of Low-Intensity Extracorporeal Shock Wave on the Treatment of Erectile Dysfunction: A Systematic Review and Meta-Analysis. Am J Mens Health. 2019 Mar-Apr;13(2):1557988319846749.
  30. Liu MC, Chang ML, Wang YC, Chen WH, Wu CC, Yeh SD. Revisiting the Regenerative Therapeutic Advances Towards Erectile Dysfunction. Cells. 2020 May 19;9(5)
  31. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. The Journal of urology. May 2012; 187(5):1769-1775.
  32. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. The journal of sexual medicine. Jan 2012;9(1):259-264.
  33. Burnett AL, Rojanasarot S, Amorosi SL. An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance. Urology. 2021 Mar;149:140-145.
  34. Sooriyamoorthy T, Leslie SW. Erectile Dysfunction. [Updated 2021 Aug 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562253/
  35. Pastuszak AW. Current Diagnosis and Management of Erectile Dysfunction. Curr Sex Health Rep. 2014;6(3):164-176. doi:10.1007/s11930-014-0023-9
  36. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433–6.
  37. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230–9.
  38. Ledda A, Belcaro G, Cesarone MR, Dugall M, Schonlau F. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010;106(7):1030–3.
  39. Jang DJ, Lee MS, Shin BC, Lee YC, Ernst E. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66(4):444–50.
  40. Lin C.-S. Advances in Stem Cell Therapy for Erectile Dysfunction. Adv. Androl. 2014;2014:140618. doi: 10.1155/2014/140618.
  41. Yafi F.A., Jenkins L., Albersen M., Corona G., Isidori A.M., Goldfarb S., Maggi M., Nelson C.J., Parish S., Salonia A. Erectile dysfunction. Nat. Rev. Dis. Primers. 2016;2:1–20. doi: 10.1038/nrdp.2016.3.
  42. Soebadi M.A., Moris L., Castiglione F., Weyne E., Albersen M. Advances in stem cell research for the treatment of male sexual dysfunctions. Curr. Opin. Urol. 2016;26:129–139. doi: 10.1097/MOU.0000000000000255.
  43. Zhang H., Albersen M., Jin X., Lin G. Stem cells: Novel players in the treatment of erectile dysfunction. Asian J. Androl. 2012;14:145–155. doi: 10.1038/aja.2011.79.
  44. Lin CS, Xin ZC, Wang Z, et al. : Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012;21(3):343–51. 10.1089/scd.2011.0303
  45. Haahr M.K., Jensen C.H., Toyserkani N.M., Andersen D.C., Damkier P., Sørensen J.A., Sheikh S.P., Lund L. A 12-Month Follow-up after a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. Urology. 2018;121:203.e6–203.e13. doi: 10.1016/j.urology.2018.06.018.
  46. Haahr M.K., Jensen C.H., Toyserkani N.M., Andersen D.C., Damkier P., Sørensen J.A., Sheikh S.P., Lund L. A 12-Month Follow-up after a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. Urology. 2018;121:203.e6–203.e13. doi: 10.1016/j.urology.2018.06.018.
  47. Bahk J.Y., Jung J.H., Han H., Min S.K., Lee Y.S. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: Preliminary report of 7 cases. Exp. Clin. Transplant. Off. J. Middle East Soc. Organ Transplant. 2010;8:150–160.
  48. Garber M.G., Carlos N.D. Intracavernous Administration of Adipose Stem Cells: A New Technique of Treating Erectile Dysfunction in Diabetic Patient, Preliminary Report of 6 Cases. MOJ Cell Sci. Rep. 2015;2:5–8.
  49. Ichim T.E., Warbington T., Cristea O., Chin J.L., Patel A.N. Intracavernous administration of bone marrow mononuclear cells: A new method of treating erectile dysfunction? J. Transl. Med. 2013;11:139. doi: 10.1186/1479-5876-11-139.
  50. Yiou R., Hamidou L., Birebent B., Bitari D., Lecorvoisier P., Contremoulins I., Khodari M., Rodriguez A.-M., Augustin D., Roudot-Thoraval F., et al. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study. Eur. Urol. 2016;69:988–991. doi: 10.1016/j.eururo.2015.09.026.
  51. Protogerou V., Michalopoulos E., Mallis P., Gontika I., Dimou Z., Liakouras C., Stavropoulos-Giokas C., Kostakopoulos N., Chrisofos M., Deliveliotis C. Administration of Adipose Derived Mesenchymal Stem Cells and Platelet Lysate in Erectile Dysfunction: A Single Center Pilot Study. Bioenergy. 2019;6:21. doi: 10.3390/bioengineering6010021.
  52. Al Demour S., Jafar H., Adwan S., AlSharif A., Alhawari H., Alrabadi A., Zayed A., Jaradat A., Awidi A. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. Urol. Int. 2018;101:358–365. doi: 10.1159/000492120.
  53. Levy J.A., Marchand M., Iorio L., Cassini W., Zahalsky M.P. Determining the Feasibility of Managing Erectile Dysfunction in Humans with Placental-Derived Stem Cells. J. Am. Osteopath. Assoc. 2016;116:e1–e5. doi: 10.7556/jaoa.2016.007.
  54. Protogerou V., Beshari S. El, Michalopoulos E., Mallis P., Chrysikos D., Samolis A.A., Stavropoulos-Giokas C., Troupis T. The Combined Use of Stem Cells and Platelet Lysate Plasma for the Treatment of Erectile Dysfunction: A Pilot Study–6 Months Results. Medicines. 2020;7:14. doi: 10.3390/medicines7030014.
  55. Yiou R., Hamidou L., Birebent B., Bitari D., Le Corvoisier P., Contremoulins I., Rodriguez A.M., Augustin D., Roudot-Thoraval F., de la Taille F., et al. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur. Urol. Focus. 2017;3:643–645. doi: 10.1016/j.euf.2017.06.009.
  56. Protogerou V, Chrysikos D, Karampelias V, Spanidis Y, Sara EB, Troupis T. Erectile Dysfunction Treatment Using Stem Cells: A Review. Medicines (Basel). 2021;8(1):2. Published 2021 Jan 6. doi:10.3390/medicines8010002
  57. Bahk J.Y., Jung J.H., Han H., Min S.K., Lee Y.S. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: Preliminary report of 7 cases. Exp. Clin. Transplant. Off. J. Middle East Soc. Organ Transplant. 2010;8:150–160.
  58. Yiou R., Hamidou L., Birebent B., Bitari D., Lecorvoisier P., Contremoulins I., Khodari M., Rodriguez A.-M., Augustin D., Roudot-Thoraval F., et al. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study. Eur. Urol. 2016;69:988–991. doi: 10.1016/j.eururo.2015.09.026.
  59. Yiou R., Hamidou L., Birebent B., Bitari D., Le Corvoisier P., Contremoulins I., Rodriguez A.M., Augustin D., Roudot-Thoraval F., de la Taille F., et al. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur. Urol. Focus. 2017;3:643–645. doi: 10.1016/j.euf.2017.06.009.
  60. Lokeshwar SD, Patel P, Shah SM, Ramasamy R. A Systematic Review of Human Trials Using Stem Cell Therapy for Erectile Dysfunction. Sex Med Rev. 2020;8(1):122-130. doi:10.1016/j.sxmr.2019.08.003
  March 28, 2022

Categories

DOCTOR
Find your doctor
Wittawat Dr. Wittawat Sithiwatcharapong,
Wit Dr. Wit Sombatworapat
Theerasak Dr. Theerasak Mongkol
Supajee Dr. Supajee Srigade
Sitt Dr. Sitt Tienthiti
Kawisara Dr. Kawisara Limapichat
Chanin Dr. Chanin Leewanun
Jane Dr. Jane Tiemrat
Chatchai Dr. Chatchai Sribundit
Chantana Dr. Chantana Somphadung
Oranee Dr. Oranee Wibuloutai
Nont Dr. Nont Rerktanom
Ubekkha Dr. Ubekkha Choomkong
Songsaeng Dr. Songsaeng Karnchanavisitphol
SEND A MESSAGE
Your email address will not be published. Required fields are marked.
CALL US : 02 651 5988
Select AH Find Dr Contact Us